Skip to content
lifestyle.realie.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nuvectis Pharma, Inc.
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
October 26, 2026
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
October 9, 2026
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
September 24, 2026
Nuvectis Pharma To Participate in Upcoming Investor Conferences
September 3, 2026
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
August 4, 2026
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
July 23, 2026
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
July 23, 2026
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
June 29, 2026
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
June 29, 2026
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
June 22, 2026
1
2
Next Page
→